Sarepta Therapeutics (SRPT)
(Delayed Data from NSDQ)
$151.48 USD
-0.26 (-0.17%)
Updated Jul 8, 2024 04:00 PM ET
After-Market: $151.42 -0.06 (-0.04%) 7:58 PM ET
3-Hold of 5 3
F Value D Growth A Momentum D VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
SRPT 151.48 -0.26(-0.17%)
Will SRPT be a Portfolio Killer in July?
Zacks Investment Research is releasing its prediction for SRPT based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for SRPT
Here's Why Sarepta (SRPT) Stock Price Surged 57% YTD
Best Momentum Stocks to Buy for July 3rd
SRPT: What are Zacks experts saying now?
Zacks Private Portfolio Services
New Strong Buy Stocks for July 3rd
Biotech Stock Roundup: ALNY Up on Study Success, ALIM on Merger News & Other Updates
Roche's (RHHBY) Ocrevus Subcutaneous Gets European Commission Nod
Other News for SRPT
Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
XPO, SRPT: 2 Stocks with a “Perfect 10” Smart Score
Strong Buy Rating for Sarepta Therapeutics Amidst Growth and Market Domination Prospects
Strong Market Position and Growth Potential Justify Buy Rating for Sarepta Therapeutics
What You Missed On Wall Street This Morning